NAME OF THE MEDICINE

AZARGA* Eye Drops is a suspension containing a combination of brinzolamide (10 mg/mL) and timolol (5 mg/mL; as timolol maleate). The chemical structure of each active ingredient is represented below:

Brinzolamide
Empirical formula: C₁₂H₂₁N₃O₅S₃
Molecular weight: 383.51
Chemical name: (R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-thieno[3,2-e]-1,2-thiazine-6-sulfonamide-1,1-dioxide
CAS Number: 138890-62-7

Timolol maleate
Empirical formula: C₁₃H₂₄N₄O₃S•C₄H₄O₄
Molecular weight: 432.50
Chemical name: (S)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2 propanol maleate (1:1) (salt)
CAS Number: 26921-17-5

DESCRIPTION

Brinzolamide is a white to off-white, crystalline powder which is very slightly soluble in water at neutral pH.

Timolol maleate is a white to off-white, crystalline powder which is soluble in water, alcohol and practically insoluble in ether.

AZARGA is a white to off-white uniform suspension for multiple-dose topical ophthalmic use. The pH of AZARGA is approximately 7.2.

AZARGA also contains mannitol, carbomer 974P, tyloxapol, disodium edetate, sodium chloride, hydrochloric acid and/or sodium hydroxide (to adjust pH), purified water and benzalkonium chloride (0.1 mg/mL) as preservative.

PHARMACOLOGY

Mechanism of Action

AZARGA contains two active substances: brinzolamide and timolol maleate. These two components decrease elevated intraocular pressure (IOP) primarily by reducing aqueous humour secretion, but do so by different mechanisms of action. Clinical data demonstrates that the combined effect of these two active substances results in additional IOP reduction compared to either compound alone.
Brinzolamide exhibits a high affinity for and is a potent inhibitor of human carbonic anhydrase II (CA-II). Carbonic anhydrase exists as a number of isoenzymes and is found in many tissues in the body; CA-II is the predominant iso-enzyme in the eye. Inhibition of CA-II in the ciliary processes of the eye decreases aqueous humour secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. Brinzolamide exhibited minimal cardiovascular effects, including no inducement of QTc prolongation and no or minimal effect on blood pressure and heart rate, and had no significant local anaesthetic (membrane stabilising) activity on the cornea.

Timolol is a non-selective beta-adrenergic receptor blocking agent that has no significant intrinsic sympathomimetic, direct myocardial depressant or local anaesthetic (membrane-stabilising) activity. The precise mechanism of action of timolol in lowering IOP is not clearly established at this time, although tonography and fluorophotometry studies suggest that its predominant action is related to reduced aqueous humour formation; a slight increase in outflow facility was also observed in some studies.

**Pharmacokinetics**

**Absorption**

Following topical ocular administration, brinzolamide and timolol are absorbed through the cornea and into the systemic circulation. In a pharmacokinetic study, healthy subjects received oral brinzolamide (1 mg) twice daily for 2 weeks to shorten the time to reach steady-state prior to starting AZARGA administration. Following twice daily dosing of AZARGA for 13 weeks, the concentrations of brinzolamide in erythrocytes at weeks 4, 10 and 15, averaged 18.8 ± 3.29 µM, 18.1 ± 2.68 µM and 18.4 ± 3.01 µM respectively. Steady state concentrations of brinzolamide in erythrocytes may not bear a simple relationship to plasma concentrations of the drug, which have been observed to be low and generally below assay quantitation limits (<10 ng/mL) following topical ocular administration in other studies.

At steady state, following administration of AZARGA, the mean plasma $C_{\text{max}}$ and $AUC_{0-12\text{h}}$ of timolol were 27% and 28% lower ($C_{\text{max}}$: 0.824 ± 0.453 ng/mL; $AUC_{0-12\text{h}}$: 4.71 ± 4.29 ng h/mL), respectively in comparison to the administration of timolol 5 mg/mL ($C_{\text{max}}$: 1.13 ± 0.494 ng/mL; $AUC_{0-12\text{h}}$: 6.58 ± 3.18 ng h/mL). The lower systemic exposure to timolol following AZARGA administration is not clinically relevant. Following administration of AZARGA, mean $C_{\text{max}}$ of timolol was reached at 0.79 ± 0.45 hours.

**Distribution**

Plasma protein binding of brinzolamide is moderate (about 60%). Brinzolamide is sequestered in red blood cells (RBCs) due to its high affinity binding to CA-II and to a lesser extent to CA-I. Its active N-desethyl metabolite also accumulates in RBCs where it binds primarily to CA-I. The affinity of brinzolamide and metabolite to RBCs and tissue carbonic anhydrase results in low plasma concentrations.

Ocular tissue distribution data in rabbits showed that timolol can be measured in aqueous humour up to 48 hours after administration of AZARGA. At steady-state, timolol is detected in human plasma for up to 12 hours after administration of AZARGA.

**Metabolism**

The metabolic pathways for brinzolamide involve N-dealkylation, O-dealkylations and oxidation of its N-propyl side chain. N-desethyl brinzolamide is a major metabolite of brinzolamide formed in humans, which also binds to CA-I in the presence of brinzolamide and accumulates in RBCs. In vitro studies show that the metabolism of brinzolamide mainly involves CYP3A4 as well as at least four other isozymes (CYP2A6, CYP2B6, CYP2C8 and CYP2C9).
Timolol is metabolised by two pathways. One route yields an ethanolamine side chain on the thiadiazole ring and the other gives an ethanolic side chain on the morpholine nitrogen and a second similar side chain with a carbonyl group adjacent to the nitrogen. Timolol metabolism is mediated primarily by CYP2D6.

**Excretion**

Brinzolamide is eliminated primarily by renal excretion (approximately 60%). About 20% of the dose has been accounted for in urine as metabolite. Brinzolamide and N-desethyl-brinzolamide are the predominant components found in the urine along with trace levels (<1%) of the N-desmethoxypropyl and O-desmethyl metabolites.

Timolol and its metabolites are primarily excreted by the kidneys. Approximately 20% of a timolol dose is excreted in the urine unchanged and the remainder excreted in urine as metabolites. The plasma t½ of timolol is 4.8 hours after administration of AZARGA*.

**CLINICAL TRIALS**

In a twelve-month, double-masked, randomised clinical trial in patients (n=437) with open-angle glaucoma or ocular hypertension who, in the investigator's opinion, could benefit from combination therapy and who had baseline mean IOP of 25 to 27 mm Hg, the mean IOP-lowering effect of AZARGA was 7 to 9 mm Hg and for dorzolamide 20 mg/mL + timolol 5mg/mL it was 7 to 9 mm Hg, when dosed twice daily. The non-inferiority of AZARGA as compared to dorzolamide 20 mg/mL + timolol 5 mg/mL in the mean IOP reduction was demonstrated across all on-therapy time-points at all visits. When evaluated at each visit, up to 60% of patients in the AZARGA group and up to 59% of patients in the dorzolamide 20 mg/mL group had IOP of less than 18 mm Hg.

In a six-month, double-masked, randomised clinical study in patients (n=523) with open-angle glaucoma or ocular hypertension and baseline mean IOP of 25 to 27 mm Hg, the mean IOP-lowering effect of AZARGA dosed twice daily was 8 to 9 mm Hg, and was up to 3 mm Hg greater than that of brinzolamide 10 mg/mL dosed twice daily and up to 2 mm Hg greater than that of timolol 5 mg/mL dosed twice daily. A statistically superior reduction (p < 0.05) in mean IOP was observed compared to both brinzolamide and timolol at all on-therapy time-points and visits throughout the study. IOP measurements conducted at 8 am, 10 am, 12 pm, 4 pm and 8 pm confirm that diurnal IOP control is superior (p < 0.05) and clinically relevant for AZARGA compared to either brinzolamide 10 mg/mL or timolol 5 mg/mL. The primary efficacy endpoint of mean IOP at 8 am and 10 am post dose for this study can be seen in Table 1 below.

**Table 1: Mean IOP (mm/Hg)**

<table>
<thead>
<tr>
<th>Visit</th>
<th>Baseline</th>
<th>Week 2</th>
<th>Month 3</th>
<th>Month 6</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>8am</td>
<td>10am</td>
<td>8am</td>
<td>10am</td>
</tr>
<tr>
<td>Azarga*</td>
<td>27.1</td>
<td>25.8</td>
<td>18.6</td>
<td>17.1</td>
</tr>
<tr>
<td>Brinzolamide</td>
<td>27.1</td>
<td>25.6</td>
<td>22.0</td>
<td>20.4</td>
</tr>
<tr>
<td>Timolol</td>
<td>27.0</td>
<td>25.4</td>
<td>20.1</td>
<td>18.8</td>
</tr>
</tbody>
</table>

* p<0.05 compared to brinzolamide and timolol at all on therapy time points
In a 7-day double masked, randomised clinical trial (n=96), the ocular comfort, based on burning and stinging, of AZARGA® was superior (p=0.0003) to that of dorzolamide 20 mg/mL + timolol 5 mg/mL. A comparison of the frequency distribution of the severity of ocular discomfort demonstrated a significant difference (p=0.0001) between the two treatment groups, with AZARGA having a lesser percentage of patients experiencing mild, moderate and severe ocular discomfort compared to dorzolamide 20 mg/mL + timolol 5 mg/mL. A significantly higher percentage of patients randomized to AZARGA experienced no ocular discomfort after 1 week of dosing (p=0.0004) compared to patients who received dorzolamide 20 mg/mL + timolol 5 mg/mL.

INDICATIONS

Decrease of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension for whom monotherapy with either component provides insufficient IOP reduction.

CONTRAINDICATIONS

A history of hypersensitivity to brinzolamide and other sulphonamides, timolol, or any other component of the medication.

The following conditions may also contraindicate the use of AZARGA:

- reactive airway disease including bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease.
- hypersensitivity to other beta-blockers.
- sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock, sino-atrial block, sick sinus syndrome.
- severe allergic rhinitis and bronchial hyperreactivity
- hyperchloremic acidosis.
- severe renal impairment (see Hepatic / Renal Impairment).

AZARGA is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.

PRECAUTIONS

FOR TOPICAL USE ONLY - NOT FOR INJECTION OR ORAL INGESTION

AZARGA should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity.

Systemic effects

Like other topically applied ophthalmic agents, brinzolamide and timolol are absorbed systemically. When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.

Brinzolamide

AZARGA contains brinzolamide, a sulphonamide. The same types of undesirable effects that are attributable to sulphonamides may occur with topical administration. Acid-base disturbances have been reported with oral carbonic anhydrase inhibitors. Use with caution in patients with risk of renal impairment because of the possible risk of metabolic acidosis. If signs of serious reactions or hypersensitivity occur, discontinue use of this medicine.

There is potential for an additive effect on the known systemic effects of carbonic anhydrase
inhibition in patients receiving an oral carbonic anhydrase inhibitor and AZARGA®. The concomitant administration of AZARGA and oral carbonic anhydrase inhibitors has not been studied and is not recommended.

Timolol

Cardiovascular Safety

Due to the beta-adrenergic component, timolol, the same types of cardiovascular and pulmonary adverse reactions as seen with systemic beta-adrenergic blocking agents may occur. Cardiac failure should be adequately controlled before beginning therapy with timolol. Patients with a history of severe cardiac disease should be watched for signs of cardiac failure and have their pulse rates checked.

In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension, therapy with beta blockers should be critically assessed and the therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.

Vascular disorders

Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud's disease or Raynaud's syndrome) should be treated with caution.

Respiratory Reactions

Respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma and, rarely, death in association with cardiac failure, have been reported following administration of timolol maleate.

Diabetes mellitus

Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycaemia or to patients with labile insulin-dependent diabetes, as beta-adrenergic blocking agents may mask the signs and symptoms of acute hypoglycaemia.

Thyrotoxicosis

Beta-adrenergic blocking agents may mask the signs of hyperthyroidism.

Muscle weakness

Beta-adrenergic blocking agents have been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g. diplopia, ptosis and generalized weakness).

Beta-adrenergic blocking agents may also cause worsening of Prinzmetal angina, severe peripheral and central circulatory disorders and hypotension.

Anaphylactic reactions

While taking beta-adrenergic blocking agents, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions.
Choroidal detachment

Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g. Timolol, acetazemide) after filtration procedures.

Surgical anaesthesia

Beta-blocking ophthalmological preparations may block systemic beta-agonist effects, e.g. of adrenaline. The anaesthesiologist should be informed when the patient is receiving timolol.

Ocular effects

AZARGA® has not been studied in patients with narrow-angle glaucoma and its use is not recommended in these patients.

There is limited experience with AZARGA in the treatment of patients with pseudoexfoliative glaucoma or pigmentary glaucoma. Caution should be utilized in treating these patients and close monitoring of IOP is recommended.

The possible role of brinzolamide on corneal endothelial function has not been investigated in patients with compromised corneas (particularly in patients with low endothelial cell count). Specifically, patients wearing contact lenses have not been studied and careful monitoring of these patients when using brinzolamide is recommended, since carbonic anhydrase inhibitors may affect corneal hydration and wearing contact lenses might increase the risk for the cornea. The use of carbonic anhydrase inhibitors can also lead to corneal decompensation and oedema. Careful monitoring of patients with compromised corneas, such as patients with diabetes mellitus or corneal dystrophies, is recommended.

Use with contact lenses

AZARGA contains benzalkonium chloride which may cause eye irritation and is known to discolor soft contact lenses. Contact with soft contact lenses is to be avoided. Patients must be instructed to remove contact lenses prior to the application of AZARGA and wait 15 minutes after instillation of the dose before reinsertion.

Effects on fertility

There are no human data on the effects of AZARGA on male or female fertility. Studies in rats, in which animals were treated orally with brinzolamide up to 18 mg/kg/day or with timolol up to 100 mg/kg/day, showed no adverse effects on male or female fertility.

Use In Pregnancy - Category C

No studies have been conducted with AZARGA in pregnant women, and no animal studies have been conducted with the combined components to evaluate effects on reproduction. Studies in animals with brinzolamide have shown reproductive toxicity following systemic administration. AZARGA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. However, if AZARGA is administered until delivery, the neonate should be carefully monitored during the first days of life.

Brinzolamide

Developmental toxicity studies with brinzolamide in rabbits at oral doses up to 6 mg/kg/day produced maternal toxicity at 6 mg/kg/day and a significant increase in the number of fetal variations, e.g. accessory skull bones; at 1 and 6 mg/kg/day, the incidence was only slightly higher than seen historically. In rats, statistically significant decreased bodyweights of fetuses from dams receiving oral doses of 18 mg/kg/day during gestation were proportional.
to the reduced maternal weight gain, with no statistically significant effects on organ or tissue development. No treatment-related malformations were seen. Exposure levels are much lower following topical administration of brinzolamide. There are no adequate data from the use of brinzolamide in pregnant women. The potential risk for humans is unknown.

**Timolol**

Timolol maleate was not teratogenic in mice, rats and rabbits. Embryofetal development studies with timolol maleate in mice and rabbits showed no evidence of embryofetal toxicity at oral doses up to 50 mg/kg/day. At higher doses, increases in resorptions and fetal variations (14 ribs and hypoplastic sternebrae) in mice (1000 mg/kg/day) and increased resorption in rabbits (≥90 mg/kg/day) were observed. In rats, delayed ossification was seen at oral doses ≥50 mg/kg/day, and decreased number of caudal vertebral bodies and arches, and an increase in hypoplastic sternebrae were noted at 500 mg/kg/day. In humans, well-controlled epidemiological studies with systemic use of beta-adrenergic blocking agents did not indicate malformative effects, but show a risk of intra uterine growth retardation. In addition, signs and symptoms of beta blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in fetuses or neonates when beta-blockers have been administered until delivery. Data on a limited number of exposed pregnancies indicate no adverse effects of timolol in eye drops on pregnancy or on the health of the fetus/newborn child but bradycardia and arrhythmia have been reported in one case in the fetus of a woman treated with timolol eye drops. To date, no other relevant epidemiological data are available.

**Use in Lactation**

It is not known whether brinzolamide is excreted in human milk following topical ocular administration. Timolol is detectable in human milk following topical ocular administration.

Studies in animals have shown that following oral administration brinzolamide is excreted in breast milk. Following oral administration of 14C-brinzolamide to lactating rats, radioactivity was found in milk at concentrations below those in the blood and plasma. Decreases in pup bodyweights were observed at 15 mg/kg/day in a prenatal and postnatal study in which rats were given brinzolamide by oral gavage at doses up to 15 mg/kg/day.

Because of the potential for serious adverse reactions in breastfed infants from brinzolamide and timolol, a decision should be made whether to discontinue breastfeeding or to discontinue AZARGA, taking into account the importance of the drug to the mother.

**Paediatric use**

AZARGA is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.

**Use in the Elderly**

There are no modifications to the recommended dosing regimen for elderly patients.

**Hepatic / Renal Impairment**

No studies have been conducted with AZARGA in patients with hepatic or renal impairment. No dosage adjustment is necessary in patients with hepatic impairment or in patients with mild to moderate renal impairment.

AZARGA has not been studied in patients with severe renal impairment (creatinine clearance <30 mL/min) or in patients with hyperchloraemic acidosis. Since brinzolamide and its main metabolite are excreted predominantly by the kidney, AZARGA is therefore
contraindicated in patients with severe renal impairment.

**Carcinogenicity**

No carcinogenicity studies have been conducted with the combined components of AZARGA.

**Brinzolamide**

A 2-year bioassay, in which rats were treated with brinzolamide by oral gavage at doses up to 8 mg/kg/day, revealed no evidence of a carcinogenic effect. A similar study conducted in mice, involving oral dosing at 0, 1, 3 or 10 mg/kg/day for 2 years, revealed a statistically significant increase in urinary bladder tumours in females at 10 mg/kg/day, and dose-related proliferative changes in the urinary bladder in females at all dose levels and among males at 10 mg/kg/day. The elevated bladder tumour incidence was primarily due to the increased incidence of a tumour and was considered to be unique to mice.

**Timolol**

No evidence of carcinogenicity was observed with timolol maleate at oral doses up to 100 mg/kg/day in rats and up to 50 mg/kg/day in mice. However, there was a statistically significant increase in the incidence of adrenal pheochromocytomas in male rats administered 300 mg/kg/day. In female mice, statistically significant increases in the incidence of benign and malignant pulmonary tumours, benign uterine polyps and mammary adenocarcinomas were found at 500 mg/kg/day. The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin, which occurred in female mice administered oral timolol at 500 mg/kg/day, but not at doses of 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin.

**Genotoxicity**

Brinzolamide did not display mutagenic potential in bacteria (Ames test) or produce chromosomal damage in vivo (mouse micronucleus test). Brinzolamide did induce forward mutations in the mouse lymphoma assay in vitro in the presence, but not in the absence, of metabolic activation. Brinzolamide was negative in a sister chromatid exchange assay in mice. Timolol was not genotoxic in assays for mutagenicity (Ames test) and clastogenicity (mouse micronucleus and cytogenic assays).

**Effects on ability to drive and use machines**

As with any eye drops, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machinery. Carbonic anhydrase inhibitors may impair the ability to perform tasks requiring mental alertness and/or physical coordination.

**Interactions with other medicines**

No drug interaction studies have been performed with AZARGA.

**Brinzolamide**

AZARGA contains brinzolamide, a carbonic anhydrase inhibitor and, although administered topically, is absorbed systemically. Acid-base disturbances have been reported with oral carbonic anhydrase inhibitors. The potential for interactions must be considered in patients receiving AZARGA.
There is a potential for an additive effect on the known systemic effects of carbonic anhydrase inhibition in patients treated with an oral carbonic anhydrase inhibitor and brinzolamide eye drops. The concomitant administration of eye drops containing brinzolamide and oral carbonic anhydrase inhibitors is not recommended.

The cytochrome P-450 isozymes responsible for metabolism of brinzolamide include CYP3A4 (main), CYP2A6, CYP2B6, CYP2C8 and CYP2C9. It is expected that inhibitors of CYP3A4 such as ketoconazole, itraconazole, clotrimazole and ritonavir will inhibit the metabolism of brinzolamide by CYP3A4. Caution is advised if CYP3A4 inhibitors are given concomitantly. However, accumulation of brinzolamide is unlikely as renal elimination is the major route. Brinzolamide is not an inhibitor of cytochrome P-450 isozymes.

**Timolol**

There is a potential for additive effects resulting in hypotension and/or marked bradycardia when eye drops with timolol are administered concomitantly with oral calcium channel blockers or beta-adrenergic blocking agents, antiarrhythmics (including amiodarone), digitalis glycosides or parasympathomimetics. The use of two local beta-adrenergic blocking agents or two local carbonic anhydrase inhibitors is not recommended.

The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta-adrenergic blocking agents.

Potential systemic beta-blockade (e.g. decreased heart rate) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, cimetidine) and timolol.

Beta-adrenergic blocking agents may increase the hypoglycaemic effect of antidiabetic agents. Beta-adrenergic blocking agents can mask the signs and symptoms of hypoglycaemia.

Beta blockers can decrease the response to adrenaline used to treat anaphylactic reactions. Special caution should be exercised in patients with a history of atopy or anaphylaxis (see Precautions: Anaphylactic reactions)

Mydriasis resulting from concomitant use of ophthalmic beta-blockers and adrenaline (epinephrine) has been reported occasionally.

**ADVERSE EFFECTS**

In two clinical trials of 6 and 12 months duration involving 394 patients treated with AZARGA Eye Drops, the most frequently reported adverse reaction was transient blurred vision upon instillation (3.6%), lasting from a few seconds to a few minutes.

The following adverse reactions were assessed to be treatment-related. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

**Psychiatric disorders:**

Uncommon (≥0.1% to <1%): insomnia

**Nervous system disorders:**

Common (≥1% to <10%): dysgeusia

Dysgeusia (bitter or unusual taste in the mouth following instillation) was a frequently reported systemic undesirable effect associated with the use of AZARGA during clinical studies. It is probably caused by passage of the eye drops in the nasopharynx via the nasolacrimal canal. Nasolacrimal occlusion and gently closing the eyelid after instillation may help reduce the incidence of this effect.
Eye disorders:

Common (≥1% to <10%): blurred vision, eye pain, eye irritation, foreign body sensation in eyes

Uncommon (≥0.1% to <1%): corneal erosion, punctate keratitis, dry eye, eye discharge, eye pruritus, ocular hyperaemia, blepharitis, allergic conjunctivitis, corneal disorder, anterior chamber flare, conjunctival hyperaemia, eyelid margin crusting, asthenopia, abnormal sensation in eye, eyelids pruritus, allergic blepharitis, erythema of eyelid, photophobia, lacrimation increased, sclera hyperaemia.

Vascular disorders:

Uncommon (≥0.1% to <1%): decreased blood pressure

Respiratory, thoracic and mediastinal disorders:

Uncommon (≥0.1% to <1%): chronic obstructive pulmonary disease, pharyngolaryngeal pain, rhinorrhoea, cough

Skin and subcutaneous tissue disorders:

Uncommon (≥0.1% to <1%): hair disorder, lichen planus

Post Marketing Experience

The following adverse reactions are classified according to the following convention: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000). Within each frequency-grouping, adverse reactions are presented in order of decreasing seriousness. These adverse reactions were obtained from clinical trials.

Blood and lymphatic system disorders:

Uncommon (≥0.1% to <1%): white blood cell count decreased

Psychiatric disorders:

Uncommon (≥0.1% to <1%): insomnia

Nervous system disorders:

Common (≥1% to <10%): dysgeusia

Eye disorders:

Common (≥1% to <10%): punctate keratitis, blurred vision, eye pain, eye irritation

Uncommon (≥0.1% to <1%): keratitis, corneal erosion, photophobia, anterior chamber flare, dry eye, vital dye staining cornea present, eye pruritus, foreign body sensation in eyes, lacrimation increased, eye discharge, erythema of eyelid, scleral hyperaemia, ocular hyperaemia, conjunctival hyperaemia.

Rare (≥0.01% to <0.1%): eyelid margin crusting.

Cardiac disorders:

Common (≥1% to <10%): heart rate decreased
**Vascular disorders:**
Uncommon (≥0.1% to <1%): blood pressure decreased

**Respiratory, thoracic and mediastinal disorders:**
Uncommon (≥0.1% to <1%): cough
Rare (≥0.01% to <0.1%): oropharyngeal pain, rhinorrhoea

**Renal and urinary disorders:**
Uncommon (≥0.1% to <1%): blood urine present

**General disorders and administration site conditions:**
Uncommon (≥0.1% to <1%): malaise

Additional adverse reactions identified from post-marketing surveillance include the following.
Frequencies cannot be estimated from the available data.

**Immune system disorders:**
Anaphylactic shock, hypersensitivity

**Cardiac disorders:**
Palpitations

**Ear and labyrinth disorders:**
Tinnitus

**Psychiatric disorders:**
Depression

**Nervous system disorders:**
Dizziness, headache, paraesthesia

**Eye disorders:**
Eye allergy, eyelid oedema, visual impairment, conjunctivitis

**Vascular disorders:**
Blood pressure increased

**Respiratory, thoracic and mediastinal disorders:**
Asthma, dyspnoea, epistaxis
Gastrointestinal disorders:
Abdominal pain upper, abdominal discomfort, diarrhoea, dry mouth, nausea

Skin and subcutaneous tissue disorders:
Alopecia, erythema, rash, pruritis

Musculoskeletal and connective tissue disorders:
Myalgia

General disorders and administration site conditions:
Chest pain, fatigue

Investigations:
Blood pressure increased

DOSAGE AND ADMINISTRATION

The recommended dosage is one drop of AZARGA\textsuperscript{*} in the conjunctival sac of the affected eye(s) twice daily. Shake the bottle well before use.

Nasolacrimal occlusion and gently closing the eyelid after instillation are recommended. This may reduce the systemic absorption of eye drops and result in a decrease in systemic adverse reactions.

If more than one topical ophthalmic medicine is being used, the medicines must be administered at least 5 minutes apart.

If a dose is missed, treatment should be continued with the next dose as planned. The dose should not exceed one drop in the affected eye(s) twice daily.

When substituting another ophthalmic antiglaucoma agent with AZARGA, the other agent should be discontinued and AZARGA should be started the following day.

To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. Instruct patients to keep the bottle tightly closed when not in use.

After cap is removed, if tamper evident snap collar is loose, remove before using product.

OVERDOSAGE

No case of overdose has been reported. A topical overdose of AZARGA may be flushed from the eye(s) with warm tap water. If an overdose with AZARGA occurs, treatment should be symptomatic and supportive. In case of accidental ingestion, symptoms of overdose from beta blockade may include bradycardia, hypotension, cardiac failure and bronchospasm.

Due to brinzolamide, electrolyte imbalance, development of an acidotic state, and possibly central nervous system effects may occur. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored. Studies have shown that timolol does not dialyse readily.

In Australia, contact Poisons Information Centre on 13 11 26; in New Zealand call 0800 POISON or 0800 764 766 for advice on management.
PRESENTATION AND STORAGE CONDITIONS

AZARGA® is presented in an 8 mL round opaque low density polyethylene DROP-TAINER® dispenser containing 5 mL suspension.

Consumer Medicine Information is supplied with this product.
AZARGA should be stored below 25oC. It can be stored in the fridge. Do not freeze.
Discard container 4 weeks after opening.

NAME AND ADDRESS OF SPONSOR

In Australia this product is supplied by:

Alcon Laboratories (Australia) Pty Ltd
54 Waterloo Rd
Macquarie Park NSW 2113

In New Zealand this product is distributed by:

Pharmaco (NZ) Ltd
4 Fisher Crescent
Auckland 1060 New Zealand
Free Phone: 0800 101 106

POISON SCHEDULE OF THE MEDICINE

Prescription Only Medicine.

DATE OF FIRST INCLUSION IN THE ARTG

Approved by TGA on 5 February 2010

DATE OF MOST RECENT AMENDMENT

18 January 2017

*a trademark of Novartis